Kyle Cromer

Assistant Professor

University of California, San Francisco

United States

Research Interests

Explore related searches

Professors in United States Professors in Tissue Engineering Tissue Engineering professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Kyle Cromer is an Assistant Professor at the University of California, San Francisco, USA. His research focuses on genome editing technologies, particularly CRISPR and AAV-mediated methods, and their applications in human hematopoietic stem and progenitor cells. Recent articles highlight his work on enhancing erythropoietic output, targeted integration strategies, and the safety of genome editing in therapeutic contexts, including treatments for sickle cell disease and β-thalassemia.

Articles (9)

Year:

2025

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

Stanford University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kyle Cromer

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Protocol for efficient CRISPR/AAV-mediated genome editing and erythroid differentiation of human hematopoietic stem and progenitor cells

Enhancement of erythropoietic output by Cas9-mediated insertion of a natural variant in haematopoietic stem and progenitor cells

Transient inhibition of 53BP1 increases the frequency of targeted integration in human hematopoietic stem and progenitor cells

CRISPR nuclease off-target activity and mitigation strategies.

Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells

Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease.

Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells.

Improved Genome Editing through Inhibition of FANCM and Members of the BTR Dissolvase Complex.

Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards.

Collaborators (5)

Richard Frock

Vivien Sheehan

Mark Behlke

Kun Jia

Jan Carette

Make your next move.